Introduction
Surgeons continually strive to improve post procedural rehabilitation in their patients, with the hope and intention of enhancing patient satisfaction and surgical outcomes. one such area that has been targeted across the surgical specialties is intra and post operative blood loss. 1 Within orthopaedic surgery, this is par ticularly relevant in patients undergoing hip and knee arthroplasty, commonly performed
Tranexamic acid toxicity in human periarticular tissues

Objectives
Tranexamic acid (TXA) is an anti-fibrinolytic medication commonly used to reduce perioperative bleeding. Increasingly, topical administration as an intra-articular injection or perioperative wash is being administered during surgery. Adult soft tissues have a poor regenerative capacity and therefore damage to these tissues can be harmful to the patient. This study investigated the effects of TXA on human periarticular tissues and primary cell cultures using clinically relevant concentrations.
Methods
Tendon, synovium, and cartilage obtained from routine orthopaedic surgeries were used for ex vivo and in vitro studies using various concentrations of TXA. The in vitro effect of TXA on primary cultured tenocytes, fibroblast-like synoviocytes, and chondrocytes was investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays, fluorescent microscopy, and multi-protein apoptotic arrays for cell death.
Results
There was a significant (p < 0.01) increase in cell death within all tissue explants treated with 100 mg/ml TXA. MTT assays revealed a significant (p < 0.05) decrease in cell viability in all tissues following treatment with 50 mg/ml or 100 mg/ml of TXA within four hours. There was a significant (p < 0.05) increase in cell apoptosis after one hour of exposure to TXA (100 mg/ml) in all tissues.
procedures that are frequently associated with considera ble blood loss. 2 Postoperative anaemia may predispose patients to an increased risk of cardiopulmonary events and adverse transfusion reactions, 3 while prolonged hos pitalization associated with significant blood loss may result in an increased risk of hospitalacquired infec tions. 4, 5 Ultimately, there may be delayed patient rehabili tation and an escalation in healthcare costs.
Activation of fibrinolysis during and after surgery is a phenomenon considered to contribute significantly to intra and postoperative blood loss. 6 Intravenous (Iv) administration of the antifibrinolytic agent (TXA) is an established offlicence perioperative haemostatic treat ment. 7 Tranexamic acid is a synthetic derivative of the amino acid lysine that inhibits fibrinolysis by competitively blocking the lysine binding site on plasminogen and subsequently inhibiting its conversion to plasmin, a fibrinolytic protease that degrades fibrin clots. It has been shown to reduce post operative bleeding and blood transfusion requirements in patients undergoing hip and knee arthroplasty. 3, 8 Despite its proven benefits, concern remains about the safety of its intravenous administration, given the documented risk of thromboembolic events and acute renal impairment. 3, 9 In view of the safety concerns relating to the intrave nous administration of TXA, it has been hypothesized that topical administration (intra/periarticular) may avoid the risks of systemic administration. Recent randomized con trolled trials investigating topical administration during hip and knee arthroplasty have demonstrated significantly lower blood loss and transfusion rates in comparison with control groups with no apparent significant systemic side effects. 10, 11 Topical TXA solution concentrations have ranged from 10 mg/ml to 200 mg/ml, with application strategies varying between studies. 3 Most topical adminis tration studies to date have focused primarily on hip and knee arthroplasty, although it is becoming increasingly popular during softtissue reconstructions such as anterior cruciate ligament (ACl) reconstruction. 12 However, unlike the majority of hip and knee arthroplasties, this involves the direct exposure of healthy cartilage, tendon, and liga ment to TXA. At present, the interaction between these important periarticular tissues and TXA remains largely unknown, with rodent and human in vitro studies on chondrocytes providing conflicting results. 1317 Adult ten don and, in particular, cartilage have a poor regenerative capacity and therefore significant damage to these tissues may be devastating to the patient. 18, 19 This study was designed to test the hypothesis that TXA had no cytotoxic effects on human periarticular tis sues including tendon, synovium, and cartilage.
Materials and Methods
Study design. All procedures and protocols were approved by the Ethics Committee under approval number REC14/ WS/1035 with informed consent obtained and carried out in accordance with standard operative procedures. tissue collection and preparation. Human tendon tissue was harvested during hamstring tendon ACl. Synovial tissue was harvested during total hip arthroplasty (THA) or total knee arthroplasty (TKA). Cartilage tissue was har vested from femoral heads obtained during hip hemi arthoplasty for femoral neck fracture. Tissues were then separated for either ex vivo or in vitro experiments as out lined below. All patients were screened and excluded if there was a prior history of surgery affecting the same joint, malignancy, or infection. Cartilage was excluded if there was any macroscopic evidence of osteoarthritis, and only outerbridge grade 0 cartilage was used. 20 tissue culture. Human tendonderived tenocytes were explanted from hamstring tendons and fibroblastlike synoviocytes (FlS) from synovial tissue, as described previously. 21 Cultures were maintained in a humidified environment at 37°C, 5% Co 2 in Roswell Park Memorial Institute (RPMI) 1640, supplemented with 10% foetal bovine serum (FBS), 1% penicillinstreptomyocin, and lglutamine (life Technologies). Cells were grown to subconfluency and passaged using trypsin ethylenedi aminetetraacetic acid (EDTA) (SigmaAldrich, Gillingham, United Kingdom). Cells from the third and fourth pas sages were seeded two days prior to experimentation and no phenotypic drift was confirmed using polymerase chain reaction (PCR; Scleraxis, Aggregan, SoX9 genes). Human chondrocytes were isolated by enzymatic digestion of intact femoral head articular cartilage. 22 Chondrocytes were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS, 1% penicillinstreptomycin, 1% amphotericin, and 10% 4(2hydroxyethyl)1piperazineethanesulfonic acid (HEPES). Cells were grown to subconfluency and detached for seeding using Accutase (SigmaAldrich). Cells from the initial explantation were not passaged. They were seeded two days prior to experimentation. Tranexamic acid was added to concentrations of 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml. Dilution groups were pHmonitored to ensure effects were not related to acidity. Confocal microscopy. Tissue samples were cut into 1 cm 2 quadruplicate replicate pieces and treated with 0 mg/ml or 100 mg/ml TXA in RPMI, supplemented with 10% FBS and 1% penicillinstreptomycin, at 37°C and 5% Co 2 for 16 hours. They were then washed in RPMI and stained with 12.5 µM 5chloromethylfluorescein diacetate (CMFDA) and 10 μMl propidium iodide 23 for two hours at 37°C, then fixed in 4% formaldehyde. They were imaged using confocal microscopy (lSM 800; Zeiss, Cambridge, United Kingdom), and the proportion of live (green) and dead (red) cells was counted using Imaris x64 (8.4.1) soft ware (Bitplane ltd, Zurich, Switzerland). Three individual donor tissues were used for the tendon and synovium, and four donors were used for the cartilage tissue. Cell viability assays. The in vitro effect of TXA at concen trations of 0 mg/ml, 1 mg/ml, 50 mg/ml, and 100 mg/ml over 1, 4, and 24 hours on primary human cell cultures was determined using 3(4,5dimethylthiazol2yl) 2,5diphenyltetrazolium bromide (MTT) cell viability assays (SigmaAldrich). 2.5 × 10 4 cells were seeded in each well of a 12well plate in a volume of 500 μl media per well. once attached, cells were treated with TXA. Culture medium was aspirated, and sterilefiltered MTT was added to each well. Cells were washed with phos phatebuffered saline (PBS) and incubated with dimethyl sulfoxide (DMSo) for ten minutes to dissolve the forma zan product. This was then transferred into a 96well plate (100 μl per well in duplicate) and read on a micro plate reader at 540 nm. Mitochondrial membrane potential assays. The mito chondrial membrane potential was measured accord ing to the manufacturer's instructions (DePsipher; R&D Systems, Inc., Minneapolis, Minnesota) by fluo rescent microscopy using a fluorescent cationic dye, 5,5′,6,6′tetrachloro1,1′,3,3′tetraethylbenzimidazolyl carbocyanine iodide (JC1). 5 ×10 4 cells/well were cul tured in 12well plates for 48 hours in the presence of increasing concentrations of TXA with medium (0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml). The cells were then washed with PBS, and reaction buffer was added with DePsipher (5 µl per sample) and stabilizer solution. The cells were incubated at room temperature, in the dark, for a minimum of 15 minutes. The cells were analyzed within one hour by fluorescent microscopy using a fluo rescein longpass filter (EvoS Fl Auto 2 Imaging System; Thermo Fisher Scientific, Waltham, Massachusetts). Using this system, cells undergoing apoptosis should appear green (585/590 nm), while healthy cells appear red (510/527 nm). Four corner random field images were saved and the number of apoptotic (green) and live (red) cells counted per image. The percentage of apop totic cells as a proportion of total cells was calculated for each image and the mean percentage calculated for each sample. Cellular apoptosis. Multiapoptotic protein detection arrays (Human Apoptosis Antibody Array Kit; R&D Systems, Inc.) were used to determine possible apoptotic pathways involved in cell death according to the manufacturer's instructions. Cells were treated with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml TXA for one hour. The protein content of each well was quantified using a Micro bicin choninic acid assay (BCA) Protein Assay Kit (Thermo Fisher Scientific) and read on a microplate reader at 540 nm. lysate protein concentrations were then normalized in lysis buffer. Cells were cultured in 12well plates for one hour, with increasing concentrations of TXA with medium (0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml). Cell supernatants were aspirated and discarded. After blocking of nonspecific binding at room temperature for one hour, antibody array membranes were incu bated with the cell lysate (1.5 ml) at 4°C overnight and then with a diluted solution of horseradish peroxidase (HRP)conjugated streptavidin at room temperature for 30 minutes. visualization of protein expression was car ried out by chemiluminescence and signal intensity was 
Results
tranexamic acid toxicity in periarticular tissues ex vivo. We first investigated whether ex vivo tissues (n = 3 tendon, synovium; n = 4 cartilage) treated with TXA displayed evidence of cytotoxicity. Treatment with 100 mg/ml of TXA for 16 hours caused a significant increase in cell death within tendon, synovium, and cartilage tissues compared with control ( Fig. 1 and Table I ). tranexamic acid toxicity in vitro. Following ex vivo experi ments, we performed time and dose curves to determine the concentration and duration of exposure to TXA at which a significant reduction in cell viability occurred.
MTT assays measuring cell metabolic activity acted as an indirect measurement of cell viability. A significant fall in cell viability occurred in all cell types at higher doses over a fourhour duration or low concentrations following 24 hours of treatment. Tenocyte viability was significantly reduced when treated with TXA at 100 mg/ml for four hours (Fig. 2) . Additionally, concentrations of 1 mg/ml, 50 mg/ml, or 100 mg/ml of TXA for 24 hours also caused a significant reduction in cell viability. Fibroblastlike synoviocyte viability was significantly reduced when treated with TXA at 1 mg/ml, 50 mg/ml, or 100 mg/ml for four hours and 50 mg/ml or 100 mg/ml for 24 hours (Fig. 2) . Furthermore, chondrocyte viability was significantly reduced when treated with TXA at 100 mg/ml for four hours and 50 mg/ml or 100mg/ml for 24 hours. There were no significant differences at one hour or with lower concentrations of TXA. Cellular death. We subsequently measured mitochon drial membrane potential as a direct measure of cellular death (apoptosis, Fig. 3 ). Tenocyte apoptosis was signifi cantly increased when cells were treated with 100 mg/ ml 
hrs
Tranexamic acid (TXA)associated periarticular apoptosis. Percentage of: a) and b) tenocyte (n = 3); c) and d) fibroblastlike synoviocyte (FlS; n = 3); and e) and f) chondrocyte (n = 4) death at a), c), e) one and b), d), f) four hours with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml TXA treatment. Dying cells (green) were calculated as a proportion of healthy (red) cells. *p < 0.05; †p < 0.01. Data represent mean ± standard error of the mean; oneway analysis of variance; Dunnett's Multiple Comparison Test. g) Fluorescent microscopy images show tenocytes, FlS, and chondrocytes at: one hour, 0 mg/ml TXA; one hour, 100 mg/ml TXA; and four hours, 100 mg/ml TXA.
for one hour or 50 mg/ml to 100 mg/ml TXA for four hours. Fibroblastlike synoviocyte and chondrocyte cell apoptosis was significantly increased when cells were exposed to 50 mg/ml or 100 mg/ml for one hour and 100 mg/ml for four hours.
Multi-protein apoptotic arrays. As fluorescent microscopy identified increased cell death at one and four hours, we carried out singlesample, multiprotein, apoptotic arrays to identify potential mechanisms that may be involved (Fig. 4) . Treatment with 0 mg/ml, 1 mg/ml, 50 mg/ml, 1 mg/ml 50 mg/ml 100 mg/ml a) Tranexamic acid (TXA)associated periarticular apoptosis pathways. Caspase3 activation induced by tranexamic acid in vitro in periarticular tissues: b) and c) tenocyte; d) and e) fibroblastlike synoviocyte (FlS); and f) and g) chondrocyte singlesample multiprotein apoptotic arrays. b), d), f) Pro caspase3 and c), e), g) cleaved caspase3 samples were treated with 0 mg/ml, 1 mg/ml, 50 mg/ml, or 100 mg/ml of TXA for one hour. Pro and cleaved forms of caspase3 signal pixel density plotted relative to control spots. HSP, heat shock protein; XIAP, Xlinked inhibitor of apoptosis protein; cIAP, cellular inhibitor of apoptosis protein; Ho1, heme oxygenase 1; HIF1α, hypoxiainducible factor 1alpha.
and 100 mg/ml of TXA for one hour caused an increase in apoptotic protein expression in tenocytes (pro caspase3, cleaved caspase3, Catalase, heat shock protein (HSP) 27, FlS cells (Xlinked inhibitor of apoptosis protein (XIAP), Survivin, cellular inhibitor of apoptosis protein (cIAP), HSP27, Catalase, heme oxygenase 1 (Ho1), HSP70 and HSP60, cleaved and pro caspase3) and chondrocytes (Ho2, Phosphorad17, hypoxiainducible factor 1alpha (HIF1α), cleaved and pro caspase3). This suggests that TXAmediated cell death may be orchestrated in part via a caspase3dependent apoptotic mechanism across all cell types.
Discussion
our study provides evidence of TXA cytotoxicity to human periarticular tissues ex vivo and in vitro at concen trations and durations of treatment routinely used in a clinical environment. Human tendon, synovium, and car tilage tissues all showed significantly higher rates of cell death when treated with TXA over a clinically relevant time period when considering the tissue halflife of TXA following Iv administration. 6 The use of TXA as an intravenous haemostatic agent during hip and knee arthroplasty is well established, with proven benefits in reduction of peri and postoperative blood loss. 3, 6 Increasingly, its use is being expanded to topical application in orthopaedic surgical procedures, 2325 which has been shown to deliver similar outcomes post operatively to those of intravenous administration. 11, 2629 Furthermore, its utilization has now expanded into topical application during softtissue surgery including arthro scopic ACl reconstruction. 30, 31 There are various methods of topical administration described in the literature, including, but not limited to, pre or postoperative injec tion, intraoperative wash, postoperative intra articular infusion through a surgical drain, and direct tissue impreg nation. 11, 28, 29, 3236 Most literature describes the administra tion of between 10 mg/ml and 100 mg/ml of TXA; however, significantly larger doses have been reported. 33 Indeed, treatment with highdose TXA (100 mg/ml) into tissues or a closed joint space may result in concentrations remaining within the synovial fluid and tissues 36 of over 1 mg/ml at up to 24 hours or longer. our findings sug gest that caution should be used when considering expos ing periarticular tissues to TXA either at high concentrations or for durations even as short as one hour. The practice of intraarticular injection or infusion, prolonged surgical soaking, or tissue impregnation, particularly when into an enclosed joint or space, should be undertaken with the knowledge of the current study and other studies that show increased cell death.
Previous studies investigating TXA cytotoxicity to resi dent periarticular tissues have produced variable results depending on animal versus human tissue and dosing regime utilized. 1317 Tuttle et al 17 found that treatment with 100 mg/ml of TXA was cytotoxic to bovine cartilage explants, and 50 mg/ml to murine chondrocytes from as early as eight hours. Ambra et al 14 treated porcine carti lage explants with 0 mg/ml to 4 mg/ml of TXA for up to six hours and found no significant increase in cytotoxic ity with live/dead cell staining and confocal microscopy. Sitek et al 13 found no obvious effect on human chondro cyte culture within gel grafts when grown in culture media containing 10 mg/ml or 20 mg/ml of TXA. More recently, Parker et al 16 described cytotoxicity in human chondrocytes in vivo and cartilage explants ex vivo at concentrations over 20 mg/ml at 12 hours' exposure. We noted decreased cell viability in tenocytes, FlS, and chondrocytes when exposed to high concentrations (100 mg/ml) over an intermediate duration (four hours), but also even at the lowest concentration (1 mg/ml) over a longer duration (24 hours). Furthermore, our study directly addresses the mechanism underlying TXAinduced cell death whereby we implicate caspase dependent apoptosis.
There are limitations inherent in our study. None of our experiments take into account the TXA being washed away in vivo; the joint space is a dynamic environment and other cell types (e.g. inflammatory cells and plate lets) could potentially have a role in TXA clearance. We do, however, know that the halflife of TXA in a closed joint following intravenous administration is around three hours and thus we feel confident that our in vitro experiments are representative.
With our ex vivo model, we had a high percentage of cell death in our tendon control. This is likely due to the effect of tissue drying between surgical harvesting and completion of graft preparation. However, this may actu ally mask the true extent of TXA toxicity in tendon tissue. It may also have been beneficial to study the ex vivo effects of TXA at additional timepoints and TXA concentrations, as was carried out with our in vitro experimentation. In addition, we acknowledge that agerelated degenerative changes may have had an influence on cell viability with regard to the synovium/cartilage obtained at THA/TKA, as they were from older patients but were constrained by our local ethics consent for obtaining tissue samples. While the current study shows increased cell death, this may not necessarily translate into poor clinical outcomes to the patient, and we recognize that studies evaluating early and longerterm clinical followup of topical TXA treated patients, particularly in softtissue orthopaedic surgery, should be undertaken in order to understand the translational potential of this basic science study.
on the basis of our findings, we would suggest that clinicians should show caution when considering topical TXA treatments, particularly on softtissue orthopaedic procedures. There is a need for further human clinical tri als in order to clarify the safety of this before it can be recommended for standard topical practice.
